Breaking
Novo Nordisk Launches Wegovy in China Before Eli Lilly, Capturing World's Largest Obesity MarketVanda Pharmaceuticals Launches NEREUS (Tradipitant) - First New Motion Sickness Drug in 40+ Years Now AvailableTakeda's TAK-881 Meets Primary Endpoint in Phase 2/3 Trial for Primary Immunodeficiency Disease
🇺🇸 FDA

Substance Use Disorders

Page 1 • 1 item

Global pharma insights on substance use disorder treatments, market trends, drug development, and regulatory updates for investors and BD professionals.

Clearmind Medicine's CMND-100 Meets Primary Endpoint in Phase I/IIa Trial for Alcohol Use Disorder
NewsAlcohol Use Disorder (AUD)Apr 15, 2026

Clearmind Medicine's CMND-100 Meets Primary Endpoint in Phase I/IIa Trial for Alcohol Use Disorder

Clearmind Medicine announces CMND-100 successfully met primary endpoint in FDA-approved Phase I/IIa trial for alcohol use disorder treatment.

James Chen, PharmD